Pharmacological Characterization of N-tert-Butyl-NЈ-[2-(4Ј- methylphenylamino)-5-nitrobenzenesulfonyl]urea (BM-573), a Novel Thromboxane A 2 Receptor Antagonist and Thromboxane Synthase Inhibitor in a Rat Model of Arterial Thrombosis and Its Effects on Bl by Jean-Michel Dogné et al.
Pharmacological Characterization of N-tert-Butyl-N-[2-(4-
methylphenylamino)-5-nitrobenzenesulfonyl]urea (BM-573), a
Novel Thromboxane A2 Receptor Antagonist and Thromboxane
Synthase Inhibitor in a Rat Model of Arterial Thrombosis and
Its Effects on Bleeding Time
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ABSTRACT
The present study was undertaken to characterize the antiplatelet
and antithrombotic effects of BM-573 [N-tert-butyl-N-[2-(4-
methylphenylamino)-5-nitrobenzenesulfonyl]urea], an original
combined thromboxane receptor antagonist and thromboxane
synthase inhibitor in rats, and to determine its effects on mice
bleeding time. Intraperitoneal injection of a single dose of 5 mg/kg
BM-573 to rats inhibited U-46619 (9,11-dideoxy-9,11-methano-
epoxy-prostaglandin F2)-induced washed platelet aggregation 30
min and 1, 2, and 4 h after drug administration with a maximum
antiplatelet effect observed after 1 and 2 h. In a rat model of
thrombosis induced by ferric chloride application on the abdom-
inal aorta, BM-573 significantly reduced the thrombus weight by
92.53, 80.20, 64.75, and 18.21% at doses of 5, 2, 0.5, and 0.2
mg/kg, respectively. Time to occlusion of abdominal aorta in the
BM-573-treated group (41.50  5.21 min) was significantly pro-
longed compared with the vehicle-treated rats (16.16  0.79 min).
Like furegrelate, seratrodast, and acetylsalicylic acid, BM-573 did
not affect the tail bleeding time induced by tail transection in mice
compared with vehicle-treated mice. Moreover, BM-573, a close
derivative of the loop diuretic torasemide, failed to induce a sig-
nificant increase in diuresis in rat and did not produce a decrease
in blood glucose concentration as observed with the sulfonylurea
glibenclamide. In conclusion, we have demonstrated that the ni-
trobenzenic sulfonylurea BM-573, an original combined throm-
boxane receptor antagonist and thromboxane synthase inhibitor,
is a potent antithrombotic agent that does not affect bleeding
time. Moreover, BM-573 lost the diuretic property of torasemide
and has no impact on glycemia.
The isozymes cyclooxygenase (COX)-1 and -2 catalyze the
conversion of arachidonic acid into thromboxane A2 (TXA2)
and prostaglandins (PGs). The eicosanoid TXA2 is the major
COX-1 product of arachidonic acid metabolism in platelets.
TXA2 is formed by the action of thromboxane synthase on the
prostaglandin endoperoxide H2 (PGH2) and causes vasocon-
striction, bronchoconstriction, and irreversible platelet ag-
gregation (Hamberg et al., 1975; Svensson et al., 1976; Bhag-
wat et al., 1985; Fiddler and Lumley, 1990). Furthermore,
recent studies have pointed out a significant stimulatory role
of TXA2 in the proliferation of vascular smooth muscle cells
and mitogenesis (Pakala and Benedict, 1998; Koba et al.,
2000). Its biosynthesis is increased in syndromes of platelet
activation, such as myocardial infarction (Eikelboom et al.,
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2002), unstable angina (Hamm et al., 1987), and thrombosis
and thrombotic disorders (Saldeen et al., 1993), but also in
other pathophysiological states, such as pulmonary hyper-
tension, asthma, and septic shock (Dogné et al., 2003). Inhi-
bition of thromboxane synthesis underlies the efficacy of
aspirin (ASA) in significantly reducing the incidence of car-
diovascular death, myocardial infarction, and stroke in high-
risk patients (Collins et al., 1994). Initially, there was great
interest in the potential use of TXA2 receptor (TP) antago-
nists such as sulotroban; however, these compounds were too
selective to completely inhibit platelet aggregation. In gen-
eral, interest has switched to agents that are combined re-
ceptor antagonists and thromboxane synthase inhibitors,
such as ridogrel and terbogrel. The rationale behind this
switch is that the TP receptor antagonist activity can block
the aggregatory and vasoconstrictor actions of both TXA2 and
PGH2. Moreover, the endoperoxide that accumulates after
inhibition of thromboxane synthesis can be converted to ei-
ther PGD2 by the platelets or prostacyclin (PGI2) by the
vessel wall, both of which increase platelet cyclic AMP levels
and inhibit platelet activation (Cheng et al., 2002, de Leval et
al., 2003, Dogné et al., 2004) (Fig. 1).
BM-573 is a molecule derived from the pyridinic sulfonyl-
urea torasemide, a loop diuretic. It is obtained by the replace-
ment of the pyridine ring of torasemide with nitrobenzene
and the presence of a tert-butyl group on the distal nitrogen
atom of the sulfonylurea moiety (Fig. 2). These modifications
improved TXA2 antagonism and revealed TXA2 synthase in-
hibitory potency. Indeed, we demonstrated that this original
molecule showed a high affinity (IC50, 1.3 nM) for the TP
receptors of human platelets. Moreover, BM-573 was found
to be a potent inhibitor of human platelet aggregation in-
duced by arachidonic acid (ED100, 0.13 M) or by the stable
TXA2 mimetic U-46619 (ED50, 0.24 M). BM-573 also re-
laxed the isolated rat thoracic aorta (ED50, 28.4 nM) con-
tracted by U-46619 and completely reduced the platelet pro-
duction of the thromboxane B2, the stable TXA2 metabolite in
blood, induced by arachidonic acid (Rolin et al., 2001).
These promising in vitro pharmacological properties led us
to study the pharmacological profile of BM-573 in vivo as an
antiplatelet and antithrombotic agent. Thus, we measured
the blood concentration of BM-573 following intraperitoneal
administration in rats at different times and evaluated the
effects on ex vivo platelet aggregation. We determined the
antithrombotic activity of our drug in a ferric chloride ab-
dominal arterial thrombosis model in rat and evaluated its
effects on bleeding time (BT) in mice. Finally, we studied the
effects of the intraperitoneal injection of BM-573 in rat on
diuresis and glycemia and compared them with those in-
duced by torasemide and the sulfonylurea glibenclamide,
respectively.
Materials and Methods
Drugs. BM-573 and torasemide [N-propyl-N-[(4-m-toluidino-3-
pyridyl)sulfonyl]urea] were synthesized in our laboratory. The sodium
salts were dissolved in propyleneglycol and diluted with physiological
saline. Furegrelate [5-(3-pyridinylmethyl)-2-benzofurancarboxylate]
and U-46619 were purchased from Cayman Chemical (Ann Arbor, MI).
They were dissolved in ethanol and diluted with physiological saline.
Acetylsalicylic acid and glibenclamide were purchased from Sigma-
Aldrich (Bornem, Belgium). Seratrodast was isolated from Bronica, a
generous gift from Takeda Chemical Industries (Osaka, Japan). The
sodium salts were dissolved in propyleneglycol and diluted with phys-
iological saline.
Animals. Male Sprague-Dawley rats weighing 250 to 300 g and 8-
to 12-week-old male and female mice were housed in a temperature-
controlled room before being used in the present experiments. All
experimental procedures and protocols used in this investigation
have been carried out in accordance with the Declaration of Helsinki
(Publication 85-23, revised 1985) and were reviewed and approved
by the Ethics Committee of the Medical Faculty of the University of
Liège (Liège, Belgium).
Ex Vivo Platelet Aggregation in Rat and BM-573 Measure-
ments. Male Sprague-Dawley rats were anesthetized with pentobar-
bital sodium (50 mg/kg, i.p.). Blood (2.5 ml) was drawn from the
abdominal aorta into a tube containing 0.3 ml of trisodium citrate
(3.2% w/v) as an anticoagulant. Platelet-rich plasma was prepared by
centrifugation at 180g for 10 min (15°C). Platelet-poor plasma was
obtained by centrifugation of remaining blood at 2205g for 10 min
(15°C). The platelet-aggregation method was modified from
Yokoyama et al. (1994). Briefly, platelet-rich plasma was centrifuged
at 1000g for 20 min, and the supernatant was discarded. The plate-
lets were suspended in washing buffer at a volume equal to the
original plasma volume and centrifuged at 1000g for 20 min. The
platelets were resuspended in a suspension buffer and adjusted to a
concentration of 5  108 cells/ml.
The washing buffer contained 137 mM NaCl, 2.7 mM KCl, 1 mM
MgCl2, 12 mM NaHCO3, 0.4 mM NaH2PO4, 0.05 trisodium citrate,
and 0.1% glucose (w/v). The pH was adjusted to 6.5 with HCl. The
suspension buffer contained 113 mM NaCl, 2.7 mM KCl, 1 mM
MgCl2, 24 mM NaHCO3, 10 mM HEPES-NaOH (pH 7.4), and 0.1%
glucose (w/v) (Li et al., 1998).
Platelet aggregation was studied using the turbidimetric method
of Born (Born and Cross, 1963) in an aggregometer Chronolog Cor-
poration (Chicago, IL) as previously described (Loı̈ et al., 1998). A
volume of 240 l of the platelet suspension was placed in a glass
Fig. 1. Arachidonic acid cascade and the cyclooxygenase pathway. TXA2
is formed by the action of thromboxane synthase on the PGH2 mainly in
activated platelets where this enzyme is highly expressed. In platelets,
PGH2 is the result of the enzymatic action of the constitutive form of
COX-1 on arachidonic acid released from the cell membrane phospholip-
ids by phospholipase A2. In endothelial cells, prostacyclin synthase can
convert PGH2 into PGI2.
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turbidity tube and warmed at 37°C for 3 min in the cells of the
aggregometer. Three minutes later, 2 l of calcium chloride solution
was added to obtain a final concentration of calcium equal to 0.2 mM.
One minute later, 10 l of U-46619 (final concentration of 1 M) was
added. Changes in light transmission were recorded 10 min after
stimulation with U-46619. The extent of aggregation was estimated
by the percentage of maximum increase in light transmission, with
the buffer representing 100% transmittance.
To examine the duration of the inhibitory effects of the BM-573 on
platelet aggregation, the drug was administered intraperitoneally in
rats 30 min and 1, 2, 4, 7, and 10 h prior to blood (2.5 ml) being drawn
from the abdominal aorta. BM-573 measurements were performed
on blood samples at the same times by using a high-performance
liquid chromatography (HPLC) technique.
Ferric Chloride-Induced Rat Arterial Thrombosis
Thrombus Weight and Histopathology. The experiments were
carried out according to the modification of the method described by
Kurz et al. (1990). Rats were anesthetized with pentobarbital sodium
(50 mg/kg, i.p.). After an abdominal midline incision, the abdominal
aorta was carefully exposed. A filter paper disk (diameter 8 mm)
saturated with 50% (w/v) ferric chloride solution was placed on the
surface of the artery for 10 min. The artery was isolated 10 min after
removing the disk, and then the rat was euthanized. The removed
abdominal artery was opened lengthwise, and the thrombus was
scraped out and placed on filter paper to remove any water. Its wet
weight was measured immediately. Results are expressed in milli-
grams of thrombus weight by kilograms of rat weight. BM-573 (5, 2,
0.5, 0.2 mg/kg), placebo, torasemide (5 mg/kg), and furegrelate (5
mg/kg) were injected intraperitoneally 1 and 2 h prior to the appli-
cation of ferric chloride.
Cross-sections of abdominal rat aorta treated with the paper filter
soaked with a solution of ferric chloride as described above were fixed
overnight in buffered formalin and embedded in paraffin. Four-
micron sections were cut and stained with hematoxylin and eosin.
Rat Abdominal Aortic Blood Flow Measurements. A filter
paper disk (diameter 8 mm) saturated with 50% (w/v) ferric chloride
solution was placed on the surface of the rat artery for 10 min
following the same procedure as described above. The rat abdominal
aortic blood flow expressed in milliliters/minute was recorded con-
tinuously by an ultrasonic Doppler flow probe (Transonic Systems
Inc., Ithaca, NY). The time to occlusion (TTO) of the abdominal aorta
was measured in minutes.
Bleeding Time in Mice. Bleeding times were assessed according
to Ma et al. (2001). Briefly, mice were placed in a holder, and their
tails were transacted with a surgical blade 1 cm proximal from the
tip. The remaining tail was immersed immediately into physiological
saline maintained at 37°C, and the time during which visible bleed-
ing was observed was measured. BM-573, furegrelate, seratrodast,
aspirin, ticlopidine, and vehicle were given intraperitoneally 1 h
prior to tail cutting.
Diuresis. Experiments were conducted as described previously
(Masereel et al., 1993). Rats (250–300 g) received an intraperitoneal
injection of BM-573 or torasemide at the dose of 5 mg/kg. Rats were
allowed free access to food and water until the beginning of the
experiment and were housed in groups of three in metabolism cages.
Urine was collected for 4 h after drug administration, and diuresis
(milliliters per kilogram) was expressed as the mean of urinary
volume (milliliters) collected from the cage.
Glycemia. The methodology was performed according to Lebrun
et al. (2000). Briefly, rats were allowed to settle in the laboratory for
at least 3 days before use. They had free access to water and received
a standard pellet diet. Conscious rats were placed in a small cabinet
60 min prior to blood sampling and throughout the duration of the
study. At zero time, BM-573 or glibenclamide were administered
intraperitoneally at a dosage of 20 mg/kg. Control animals received
an equivalent volume of water and propyleneglycol (50% total vol-
ume; 1.5 ml/kg body weight). Blood was taken from the tail at time
5, 30, 60, 120, and 180 min. Blood glucose was measured in duplicate
using a reagent strip in combination with a glucometer (Gluco Touch;
LifeScan, a Johnson & Johnson Company, Beerse, Belgium).
Statistical Analysis. Results are expressed as the mean 
S.E.M., and statistical significance was determined by Student’s t
test and the chi-square test. Probability values of less than 0.05 were
considered to be significant.
Results
Ex Vivo Platelet Aggregation in Rat and BM-573
Blood Measurements. Intraperitoneal injection of a single
dose of 5 mg/kg BM-573 to rats inhibited U-46619-induced
washed platelet aggregation 30 min and 1, 2, and 4 h after
drug administration. The maximum antiplatelet effect was
observed 1 and 2 h after BM-573 administration (Fig. 3).
Blood levels of BM-573 measured by HPLC were maximum
1 h after BM-573 injection and decreased time-dependently
after this period (Fig. 4).
Antithrombotic Effect of BM-573
Thrombus Weight. The application of ferric chloride (50%
w/v) for 10 min to the abdominal aorta induced marked thrombi
in vehicle-treated rats (8.3973  0.369 mg/kg). In this group,
the mixed thrombi composed of both fibrin and platelets were
adherent to the vessel wall at the site of ferric chloride contact,
as revealed by light micrographs of abdominal rat aorta sections
stained with hematoxylin-eosin (Fig. 5).
The intraperitoneal injection of BM-573 at doses of 5, 2,
Fig. 2. Chemical structures of the pyridinic sulfonylurea torasemide and the nitrobenzenic sulfonylurea BM-573.
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0.5, and 0.2 mg/kg 1 h before ferric chloride application
resulted in a significant reduction of thrombus weight by
92.53, 80.20, 64.75, and 18.21%, respectively. When BM-573
was administered intraperitoneally 2 h before ferric chloride
treatment at doses of 5 and 2 mg/kg, the thrombus weight
was reduced by 61.34 and 44.58%, respectively. No signifi-
cant effects were observed with torasemide, furegrelate, or
seratrodast on thrombus formation when administered intra-
peritoneally at 5 mg/kg 1 or 2 h before thrombus induction
(Fig. 6).
Time to Occlusion. TTO of the abdominal aorta in vehi-
cle-treated rats ranged from 13 to 18 min after the filter
paper was soaked in a 50% solution of FeCl3 application with
an average TTO of 16.16  0.79 min. After an intraperitoneal
injection of 5 mg/kg BM-573 1 h before ferric chloride appli-
cation, the average TTO measured was 41.50  5.21 min. In
the same conditions, torasemide, seratrodast, and furegre-
late did not prolong TTO.
Effect of BM-573 on Bleeding Time in Mice. BM-573,
furegrelate, seratrodast, and acetylsalicylic acid (5 mg/kg,
i.p., 1 h pretreatment) did not affect the tail BT induced by
tail transection in mice compared with vehicle-treated mice.
Aspirin tended to prolong the tail bleeding time, although its
effect failed to reach significance. In the same conditions,
ticlopidine significantly prolonged BT up to 247 s (Fig. 7).
Diuretic Properties of BM-573 in Rat. Diuretic proper-
ties of BM-573 and torasemide were studied time-depen-
dently after intraperitoneal administration of 5 mg/kg in rat.
Figure 8 shows that the single intraperitoneal administra-
tion of torasemide induced a significant increase in diuresis
in rat. Cumulated urine volumes measured in the BM-573-
treated group do not differ from those in the vehicle-treated
group.
Effects of BM-573 on Blood Glucose Concentration.
In control rats receiving the vehicle, the blood glucose level
was stable for 180 min. The glycemia averaged 115.2  9.7
mg/100 ml at the 5th min and 109.4  16.6 mg/100 ml at the
180th min. The intraperitoneal injection of BM-573 did not
provoke a decrease in glycemia. The blood glucose level
amounted to 116.6  12.3 mg/100 ml at the 5th min and
105.2  11.9 mg/100 ml at the 180th min. The hypoglycemic
effect of glibenclamide observed was rapid and marked. At
the 60th min, the glycemia averaged 67.4  7.8 mg/100 ml
after the administration of 20 mg/kg (Fig. 9).
Discussion
Thromboxane A2 is both a powerful aggregating mediator
and a constrictor of blood vessels. TXA2 levels are elevated in
conditions associated with platelet activation leading to
thrombosis, including unstable angina, myocardial infarc-
tion, and cerebral ischemia. Aspirin is the most common drug
used to prevent TXA2 production. Indeed, low doses of aspirin
selectively inhibit the formation of TXA2 via cyclooxygen-
ase-1 inhibition without altering the basal biosynthesis of
cardioprotective prostacyclin produced via cyclooxygenase-2
by endothelial cells. Furthermore, ASA causes complete en-
zyme inhibition, without the recovery of enzyme activity. The
effect of ASA in the prevention of ischemic events has been
well documented in many older and recent clinical trials. It is
clear from these studies that ASA, alone or in combination
with other antithrombotics, significantly reduces the inci-
dence of cardiovascular death, stroke, and myocardial infarc-
tion (Mangano, 2002; Gorelick PB et al., 2003). Thus, acetyl-
salicylic acid has been a drug of choice as an antiplatelet
agent; however, aspirin sensitivity has been noted as leading
to asthma and Reye’s syndrome (Pinsky et al., 1988). More-
over, ASA use is associated with gastroduodenal mucosal
damage and increased risk of upper gastrointestinal bleeding
(Awtry and Loscalzo, 2000). Since inhibition of thromboxane
synthesis underlies the efficacy of aspirin, specific thrombox-
ane receptor antagonists (TXRAs) such as seratrodast and
thromboxane synthase inhibitors (TXSIs) such as ozagrel
have been developed. Both thromboxane receptor antago-
nists and thromboxane synthase inhibitors show interesting
pharmacological characteristics. TXSIs can result in an in-
crease of the synthesis of the antiaggregatory and vasodila-
tory prostacyclin, and TXRAs can block the action of both
TXA2 and PGH2 at a receptor level. A solution to thereby
optimize the therapeutic benefit of both types of agents used
alone was to combine their properties in the same molecule.
Indeed, to support this concept, a series of double-blind,
placebo-controlled, crossover studies in healthy volunteers
was carried out using a coadministration of the TXRA su-
lotroban and the TXSI dazoxiben. Results obtained con-
Fig. 3. Time-dependent effect of BM-573 on platelet aggregation induced
in rat washed platelets by U-46619. Each column represents the mean 
S.E.M. of 6 to 7 rats. , P  0.05 compared with the vehicle-treated group.
Fig. 4. Blood levels of BM-573 (g/ml) determined by HPLC. Mean 
S.E.M. (n  6). , P  0.05 compared with the vehicle-treated group.
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Fig. 5. A, longitudinal section of an aorta show-
ing a subocclusive thrombus induced by FeCl3
(brown linear deposit, arrow) (hematoxylin and
eosin, original magnification 50). B, high-
power view of the thrombus showing a mesh-
work of fibrin (arrows) associated with large ag-
gregates of platelets (P) and red blood cells
(RBC) (hematoxylin and eosin, original magnifi-
cation 200).
Fig. 6. A, dose-dependent effects of BM-573 on
thrombus weight (milligrams per kilogram) 1
(white columns) and 2 h (gray columns) before
ferric chloride application on rat abdominal
aorta. B, effects of seratrodast, torasemide, and
furegrelate (5 mg/kg, i.p.) on thrombus weight
(milligrams per kilogram) 1 (white columns) and
2 h (gray columns) before ferric chloride applica-
tion on rat abdominal aorta. Each column repre-
sents the mean  S.E.M. of 6 to 7 rats. , P 
0.05 compared with the vehicle-treated group.
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firmed the greater interest for coadministration of both
thromboxane modulators than their independent use (Dogné
et al., 2000, 2003).
In previous in vitro and ex vivo studies, it has been dem-
onstrated that BM-573 was a potent combined compound
capable of reducing TXA2 production by thromboxane inhibi-
tion and preventing the action of TXA2 (or PGH2) by blocking
the TXA2 receptors. The present study demonstrated that
this dual TXA2 receptor antagonist and thromboxane syn-
thase inhibitor prevents platelet aggregation and thrombus
formation without affecting bleeding time. Indeed, intraperi-
toneal injection of BM-573 (5 mg/kg) to rats inhibited
U-46619-induced washed platelet aggregation. The maxi-
mum antiplatelet effect was observed 1 and 2 h following
BM-573, corresponding to the higher blood levels of BM-573
assayed by HPLC. This result indicates that BM-573 is active
as TXRA in vivo and is rapidly metabolized after i.p. injec-
tion. Indeed, BM-573 blood levels decrease significantly 2 h
following the injection, and the ex vivo antiplatelet effect
cannot be observed after 7 h. In support of these pharmaco-
kinetic data, we evaluated the antithrombotic effect of BM-
573 on ferric chloride-induced arterial thrombosis in rats. We
chose this model because the development of thrombi in
response to ferric chloride-induced vascular injury was de-
scribed to be physiologically relevant (Kurz et al., 1990). In
this model, we observed that the application of ferric chloride
to the abdominal aorta induced marked mixed thrombi com-
posed of activated platelets, fibrin strands, and entrapped
erythrocytes. These thrombi were adherent to the vessel wall
at the site of ferric chloride contact, as revealed by light
micrographs of abdominal rat aorta sections (Fig. 5). By
using a ferric-chloride solution concentration of 50% w/v, the
time to form an occlusive thrombus that induced the occlu-
sion of rat abdominal aorta was less than 20 min in all
experiments, with an average of 16.16 min. This result is in
accordance with the data of Tanaka and collaborators, who
performed a similar thrombus model in rats (Tanaka et al.,
2000). In our study, BM-573 clearly prevented thrombus
formation following ferric chloride-induced vascular injury,
with maximum activity observed when injected 1 h before
thrombus formation. Both the histopathological examination
and time to occlusion measurements confirmed this anti-
thrombotic effect. Moreover, the TXRA seratrodast and TXSI
furegrelate were inactive. This result confirms our previous
data supporting that seratrodast, an antiasthmatic agent,
was a weak human platelet thromboxane receptor antagonist
(Dogné et al., 2003). Furegrelate is a weak TXSI that only
prevents human platelet aggregation induced by arachidonic
acid or U-46619 at high concentrations. These findings sug-
gest that potent thromboxane modulators such as BM-573
are effective in preventing acute and mixed-type arterial
thrombosis. Our results are supported by two previous re-
ports indicating that, in a similar rat model of ferrous chlo-
ride-induced artery thrombosis, two selective TP antago-
nists, Z-335, given orally, and BMS-180291, given
intravenously, decreased the weight of arterial thrombi
(Tanaka et al., 2000). We thereafter examined the effects of
BM-573 at the antithrombotic dose of 5 mg/kg on bleeding
time in mice compared with seratrodast, furegrelate, aspirin,
and ticlopidine. The bleeding time measured in the vehicle-
group (129.3  15.4 s) was coherent with results obtained by
Ma et al. (2001). In this test, all thromboxane modulators
failed to prolong bleeding time. Aspirin tended to prolong the
tail bleeding time, although its effect was not statistically
significant. These results confirm that TXA2/PGI2 balance is
not a major factor in the regulation of bleeding time in acute
models (Tanaka et al., 1998). The causes of the separation of
antithrombotic and bleeding time effects of BM-573 remain
unknown. In contrast, ticlopidine, an ADP receptor antago-
nist, significantly increased bleeding time tendency, as ob-
served by different authors (Kim et al., 1998; Foster et al.,
2001). Finally, we examined both the diuretic and hypogly-
cemic properties of BM-573 compared with torasemide and
glibenclamide, respectively. Indeed, BM-573 was originally
designed from a pharmacomodulation study of the loop di-
uretic torasemide that was found to be a weak thromboxane
receptor antagonist at a nontherapeutic dosage (Uchida et
al., 1992). Thus, the diuretic effects of torasemide and BM-
573 were compared in rats over 10 h after intraperitoneal
injection of a single dose of 5 mg/kg. As expected, torasemide
produced a significant increase in urinary volume over the
10-h period, whereas diuresis induced by BM-573 was not
Fig. 7. Effect of BM-573, furegrelate, seratro-
dast, acetylsalicylic acid, and ticlopidine (5 mg/
kg, i.p., 1 h pretreatment) on tail bleeding time in
mice. Mean  S.E.M. (n  6). , P  0.05 com-
pared with the vehicle-treated group.
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different from the vehicle-treated group. From a pharmaco-
logical point of view, torasemide is a diuretic that acts by
inhibiting NaK2Cl cotransport in the thick ascending
limb of the loop of Henle. Thus, it can be postulated that
BM-573 lost the diuretic property of torasemide because of a
lack of affinity for the NaK2Cl cotransport in the thick
ascending limb of the loop of Henle (Wittner et al., 1986).
This hypothesis can be explained on the basis of the struc-
ture-activity studies realized on torasemide derivatives. In-
deed, torasemide is a pyridine-3-sulfonylurea derivative.
Several studies demonstrated that the sulfonylurea moiety
can be substituted by a sulfonylthiourea or a sulfonylcya-
noguanidine without dramatically affecting the diuretic
properties of torasemide (Masereel et al., 1993). Neverthe-
less, Wittner and collaborators demonstrated that if the pyri-
dine ring is replaced by a NO2-substituted phenyl ring such
as with BM-573, the inhibitory potency for the NaK2Cl
cotransport system of the cortical thick ascending limb was
lost (Wittner et al., 1987). In vivo experiments performed by
our group with other nitrobenzenic sulfonylurea derivatives
also confirmed the loss of the diuretic property. The oral
hypoglycemic glibenclamide, a specific blocker of the ATP-
sensitive K channel, is the other sulfonylurea derivative
that emerged as original TXRA. Indeed, in isolated ring seg-
ments of dog coronary artery, glibenclamide has been shown
to cause a reduction of both spontaneous isometric force and
contractions induced by U-46619 (Cocks et al., 1990; Stanke
et al., 1998). Thus, the aim of the last experiment was to
evaluate the hypoglycemic property of the sulfonylurea BM-
573 compared with glibenclamide in rats. In this test,
whereas the hypoglycemic effect of glibenclamide injected in
rats was rapid and marked, as observed by Lebrun et al.
(2000), BM-573 failed to produce a decrease in blood glucose
concentration.
In conclusion, we have demonstrated that the nitroben-
zenic sulfonylurea BM-573 is a potent antithrombotic agent
that does not affect bleeding time. These effects observed in
vivo can be explained by the pharmacological properties of
BM-573 at a cellular level. It was indeed characterized as an
original combined thromboxane receptor antagonist and
thromboxane synthase inhibitor. Moreover, BM-573 lost the
diuretic property of torasemide and has no impact on glyce-
mia. The chemical structure of BM-573 offers a new template
for the design of original and potent TXA2 modulators useful
in thrombotic disorders.
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Dogné JM, de Leval X, Kolh P, Sanna V, Rolin S, Michaux C, Mauer M, David JL,
Masereel B, and Pirotte B (2003) Pharmacological evaluation of the novel throm-
boxane modulator BM-567 (I/II). Effects of BM-567 on platelet function. Prosta-
glandins Leukotrienes Essent Fatty Acids 68:49–54.
Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, and Yusuf S (2002) Aspirin-
resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke,
or cardiovascular death in patients at high risk for cardiovascular events. Circu-
lation 105:1650–1655.
Fiddler GI and Lumley P (1990) Preliminary clinical studies with thromboxane
synthase inhibitors and thromboxane receptor blockers. A review. Circulation
(Suppl 1) 81:I69–78.
Foster CJ, Prosser DM, Agans JM, Zhai Y, Smith MD, Lachowicz JE, Zhang FL,
Gustafson E, Monsma FJ Jr, Wiekowski MT, et al. (2001) Molecular identification
and characterization of the platelet ADP receptor targeted by thienopyridine
antithrombotic drugs. J Clin Investig 107:1591–1598.
Gorelick PB, Richardson D, Kelly M, Ruland S, Hung E, Harris Y, Kittner S, and
Leurgans S (2003) Aspirin and ticlopidine for prevention of recurrent stroke in
black patients: a randomized trial. JAMA 289:2947–2957.
Hamberg M, Svensson J, and Samuelsson B (1975) Thromboxanes: a new group of
biologically active compounds derived from prostaglandin endoperoxides. Proc
Natl Acad Sci USA 72:2994–2998.
Hamm CW, Lorenz RL, Bleifeld W, Kupper W, Wober W, and Weber PC (1987)
Fig. 8. Diuresis (milliters per kilogram) measured in a time-dependent
study in rats pretreated by a single dose (5 mg/kg) of BM-573 or to-
rasemide. Columns represent the mean  S.E.M. of the cumulated urine
volumes (n  9). , P  0.05 compared with the vehicle-treated group.
Fig. 9. Time courses of the changes in blood glucose level in fed rats
injected intraperitoneally at time 0 with BM-573 (20 mg/kg), gliben-
clamide (20 mg/kg), or the vehicle. Mean  S.E.M. (n  6). , P  0.05
compared with the vehicle-treated group.
504 Dogné et al.
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